PITTSBURGH, April 3, 2012 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that its Mylan Institutional business has launched Mesna Injection, 100 mg/mL, packaged in 1,000 mg/10mL multiple-dose vials. This product, which has faced recent shortages in the U.S., is the generic version of Baxter Healthcare Corporation's Mesnex Injection® and is indicated as a prophylactic agent in reducing the incidence of ifosfamide-induced hemorrhagic cystitis.

Mesna Injection, 100 mg/mL, had U.S. sales of approximately $11.7 million for the 12 months ending Dec. 31, 2011, according to IMS Health. Mylan has begun shipping its generic version, which has been approved by the U.S. Food and Drug Administration (FDA), presented in 10-vial packs.  

Currently, Mylan has 173 ANDAs pending FDA approval representing $100.2 billion in annual sales, according to IMS Health. Forty-two of these pending ANDAs are potential first-to-file opportunities, representing $26.9 billion in annual brand sales, for the 12 months ending Dec. 31, 2011, according to IMS Health.

Mylan Inc. ranks among the leading generic and specialty pharmaceutical companies in the world and provides products to customers in more than 150 countries and territories. The company maintains one of the industry's broadest and highest quality product portfolios supported by a robust product pipeline; operates one of the world's largest active pharmaceutical ingredient manufacturers; and runs a specialty business focused on respiratory, allergy and psychiatric therapies. For more information about Mylan, please visit www.mylan.com. For more information about generic drugs, please visit www.ChoosingGenerics.com.

SOURCE Mylan Inc.